androsterone glucuronide has been researched along with Cancer of Prostate in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (50.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Friedman, GD; Guess, HA; Imperato-McGinley, J; Lobo, RA; Orentreich, N; Sadler, MC; Stanczyk, FZ; Vogelman, JH | 1 |
Gallagher, RP; John, EM; Kolonel, LN; Stanczyk, FZ; West, DW; Whittemore, AS; Wu, AH | 1 |
BĂ©langer, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 2 |
4 other study(ies) available for androsterone glucuronide and Cancer of Prostate
Article | Year |
---|---|
5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.
Topics: Aged; Aged, 80 and over; Androsterone; Biomarkers, Tumor; Case-Control Studies; Cholestenone 5 alpha-Reductase; Confounding Factors, Epidemiologic; Humans; Male; Middle Aged; Odds Ratio; Oxidoreductases; Prostatic Neoplasms; Reproducibility of Results; Testosterone | 1997 |
Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men.
Topics: Age Distribution; Aged; Aged, 80 and over; Aging; Analysis of Variance; Androstane-3,17-diol; Androsterone; Asian People; Biomarkers; Black People; British Columbia; California; Case-Control Studies; Cholestenone 5 alpha-Reductase; Hawaii; Humans; Life Style; Male; Middle Aged; Oxidoreductases; Population Surveillance; Prostatic Neoplasms; Reference Values; Risk Assessment; Risk Factors; Sensitivity and Specificity; White People | 2001 |
Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.
Topics: Aged; Aminoglutethimide; Androstane-3,17-diol; Androstanols; Androsterone; Anilides; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Flutamide; Glucuronates; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms | 1987 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |